Phase 3 Study of ALXN1850 Versus Placebo in Adolescent and Adult Participants With HPP Who Have Not Previously Been Treated With Asfotase Alfa

Study Identifier:
D8590C00002
ClinicalTrials.gov Identifier:
NCT06079281
EudraCT Identifier:
N/A
Sponsor:
Alexion Pharmaceuticals, Inc.
Study Contact Information:
N/A
Recruitment Complete

Study Details

Medical Condition
  • Unmapped
Study Drug
  • Drug: ALXN1850
  • Drug: Placebo
Date
Jan 2024 - Jul 2025
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 12 - 130 Years
Requirements Information
Sex
Female & Male
Age
12 - 130 Years

Study Details

Medical Condition
  • Unmapped
Study Drug
  • Drug: ALXN1850
  • Drug: Placebo
Date
Jan 2024 - Jul 2025
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 12 - 130 Years years
Requirements Information

Protocol Summary

The primary objective of this study is to assess the efficacy of ALXN1850 versus placebo on functional outcomes in adolescent and adult participants with HPP who have not previously been treated with asfotase alfa.

Trial Locations

Location
Status
Location
Research Site
Indianapolis, Indiana, United States, 46202
Status
N/A
Location
Research Site
Garden City, New York, United States, 11530
Status
N/A
Location
Research Site
Durham, North Carolina, United States, 27705
Status
N/A
Location
Research Site
Columbus, Ohio, United States, 43203
Status
N/A
Location
Research Site
Nashville, Tennessee, United States, 37212
Status
N/A
Location
Research Site
Buenos Aires, Argentina, C1199
Status
N/A